Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastati
European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective...
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA")...
Bitmine Immersion Technologies Announces Initial Dividends and NYSE Listing for Series A Preferred Stock
Bitmine's Board of Directors declares initial cash dividends on the Company's 9.50% Series A Perpetual Preferred Stock Series A Preferred Stock approved for listing on the New York Stock Exchange under the symbol "BMNP" with trading expected to...
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
HONG KONG, June 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for...
Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
GUANGZHOU, China, June 4, 2026 /PRNewswire/ -- Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult...
Bulletin from the Extraordinary General Meeting of AB Electrolux
The Extraordinary General Meeting of AB Electrolux was held in Stockholm on May 27, 2026 STOCKHOLM, May 27, 2026 /PRNewswire/ -- Amendment of the Articles of Association The General Meeting resolved, in accordance with the Board's proposal, to...
Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal
Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal SHANGHAI, April 20, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance" or the "Company") announces that CHEST, the official...
Ericsson's Annual General Meeting 2026
STOCKHOLM, April 1, 2026 /PRNewswire/ -- Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) (the "Company") held its Annual General Meeting ("AGM") today on March 31, 2026 in Kista, Stockholm. Shareholders were also able to exercise their voting rights...
New General Level Health Claim for Soy in Australia and New Zealand
New Claim Reaffirms the Positive Role of Soy Protein for Heart Health CHESTERFIELD, Mo., March 31, 2026 /PRNewswire/ -- The U.S. Soybean Export Council (USSEC) and Soy Nutrition Institute Global (SNI Global) applaud a new general level soy heart...
Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products...